



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/752,533
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	December 29, 2000
				First Named Inventor	Stephen M. COUTTS
				Art Unit	655 1654
				Examiner Name	D. Lukton
Sheet	1	of	2	Attorney Docket Number	252312005704


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DL	1.	US-2003/0103990-A1	06-05-2003	Coutts et al.	
	2.	US-2004/0208864-A1	10-21-2004	Strand et al.	
	3.	US-2004/0224366-A1	11-11-2004	Jones et al.	
	4.	US-2004/0258683-A1	12-23-2004	Linnik et al.	
	5.	US-2005/0004351-A1	01-06-2005	Marquis et al.	
	6.	US-2005/0026856-A1	02-03-2005	Coutts et al.	
DL	7.	US-2005/0031635-A1	02-10-2005	Coutts et al.	
	8.	US-6,858,210-B1	02-22-2005	Marquis et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
X	9.	DB-287-850-A5	03-14-1994	Akademie der Wissenschaften der DDR		✓

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
DL	10.	Calvin, N.M. et al. (1987). "Photoadducts of 8-Methoxypsoralen to Cytosine in DNA," <i>Photochemistry and Photobiology</i> 45(3):323-330.			
	11.	Food and Drug Administration (October 13, 2004). Information from United States Food and Drug Administration, 2 pages.			
	12.	La Jolla Pharmaceutical Company Press Release. (March 31, 2003). "Results From Two Riquent™ Trials Show Lupus Patients With Sustained Reductions In Antibodies To dsDNA Have Fewer Renal Flares," San Diego, CA, 4 pages.			
	13.	La Jolla Pharmaceutical Company Press Release. (February 18, 2003). "La Jolla Pharmaceutical Announces Results of Phase III Trial of Riquent™," San Diego, CA, 5 pages.			
	14.	La Jolla Pharmaceutical Company Press Release. (August 2, 2004). "La Jolla Pharmaceutical Reaches Agreement with Cardio-Renal Division of FDA Regarding Phase 4 Trial Design Under Special Protocol Assessment," San Diego, CA, 3 pages.			
	15.	La Jolla Pharmaceutical Company Press Release. (October 14, 2004). "La Jolla Pharmaceutical Company Receives Letter From FDA About Riquent," San Diego, CA, 2 pages.			
	16.	La Jolla Pharmaceutical Company Press Release. (November 23, 2004). "La Jolla Pharmaceutical Company Provides Update on Riquent Program," San Diego, CA, 3 pages.			
	17.	La Jolla Pharmaceutical Company Press Release. (March 14, 2005). "La Jolla Pharmaceutical Announces Outcome of Recent FDA Discussions," San Diego, CA, 2 pages.			
DL	18.	La Jolla Pharmaceutical Company Press Release. (May 31, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent," San Diego, CA, 3 pages.			
	19.	Office Action mailed on July 18, 2000 for U.S. Patent Application No. 09/457,875, 7 pages.			
Examiner Signature	David Lukton			Date Considered	11-18-05

pa- 1008332



ALTERNATIVE TO PTO/SB/08a/b (07-05)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/752,533		
		Filing Date	December 29, 2000		
		First Named Inventor	Stephen M. COUTTS		
		Art Unit	1653		
		Examiner Name	D. Lukton		
Sheet	2	of	2	Attorney Docket Number	252312005704

20.	Office Action mailed on October 5, 2001 for U.S. Patent Application No. 09/766,365, 5 pages.	
21.	Office Action mailed on February 22, 2005 for U.S. Patent Application No. 10/219,238, 13 pages.	
22.	Ostrander, E.A. et al. (1993). "Identification and Characterization of Dinucleotide Repeat (CA) _n Markers for Genetic Mapping in Dog," <i>Genomics</i> 16:207-213.	
23.	U.S. Patent Application No. 09/724,822 filed November 28, 2000 by Linnik et al.	
24.	U.S. Patent Application No. 10/846,079, filed May 13, 2004 by Victoria et al.	
25.	U.S. Patent Application No. 10/957,198, filed October 1, 2004 by Barstad et al.	
26.	U.S. Patent Application No. 11/073,332, filed March 4, 2005 by Jones.	
27.	U.S. Patent Application No. 11/081,309 filed March 15, 2005 by Linnik et al.	
28.	U.S. Patent Application No. 11/144,155, filed June 2, 2005 by Engle et al.	
29.	U.S. Patent Application No. 11/149,779, filed June 10, 2005 by Jones.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

11-18-05

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-1008332